BR0207422A - Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição - Google Patents

Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição

Info

Publication number
BR0207422A
BR0207422A BR0207422-2A BR0207422A BR0207422A BR 0207422 A BR0207422 A BR 0207422A BR 0207422 A BR0207422 A BR 0207422A BR 0207422 A BR0207422 A BR 0207422A
Authority
BR
Brazil
Prior art keywords
igf
dimensional structure
chemical entity
identification
agonist
Prior art date
Application number
BR0207422-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Michelle Schaffer
Mark Ultsch
Felix Vajdos
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR0207422A publication Critical patent/BR0207422A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
BR0207422-2A 2001-02-09 2002-02-01 Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição BR0207422A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26797701P 2001-02-09 2001-02-09
US28707201P 2001-04-27 2001-04-27
PCT/US2002/003156 WO2002064627A2 (en) 2001-02-09 2002-02-01 Crystallization of igf-1

Publications (1)

Publication Number Publication Date
BR0207422A true BR0207422A (pt) 2005-04-19

Family

ID=26952796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207422-2A BR0207422A (pt) 2001-02-09 2002-02-01 Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição

Country Status (19)

Country Link
US (8) US7084240B2 (enExample)
EP (3) EP1801120A1 (enExample)
JP (2) JP4489352B2 (enExample)
KR (1) KR100872613B1 (enExample)
CN (1) CN100439397C (enExample)
AT (2) ATE439378T1 (enExample)
AU (1) AU2002255508B2 (enExample)
BR (1) BR0207422A (enExample)
CA (1) CA2431033A1 (enExample)
DE (3) DE60217066D1 (enExample)
DK (2) DK1772464T3 (enExample)
ES (2) ES2278020T3 (enExample)
HU (1) HUP0500733A3 (enExample)
IL (2) IL156435A0 (enExample)
MX (1) MXPA03007042A (enExample)
NZ (3) NZ526672A (enExample)
PL (1) PL374181A1 (enExample)
WO (1) WO2002064627A2 (enExample)
ZA (1) ZA200304900B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401476A4 (en) * 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
DE60224419D1 (de) * 2001-09-18 2008-02-14 Bioexpertise Llc Von igf-bindungsprotein stammendes peptid
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
CA2565308A1 (en) * 2003-05-06 2004-11-25 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
WO2005041895A2 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
ES2348303T3 (es) 2003-12-08 2010-12-02 Cpex Pharmaceuticals, Inc. Composiciones farmacauticas y procedimientos de tratamiento con insulina.
WO2005108424A1 (en) * 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060003931A1 (en) * 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
WO2006039622A2 (en) * 2004-10-01 2006-04-13 Invitrogen Corporation Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
US7556776B2 (en) * 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
WO2009026172A2 (en) * 2007-08-17 2009-02-26 The Regents Of The University Of California New approach for designing diabetes drugs
CN101139391B (zh) * 2007-08-21 2012-07-25 陈志南 Cd147胞外区晶体结构及应用
WO2009134395A2 (en) 2008-04-28 2009-11-05 President And Fellows Of Harvard College Microfluidic device for storage and well-defined arrangement of droplets
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
JP5571186B2 (ja) * 2009-07-22 2014-08-13 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体
WO2011047204A1 (en) * 2009-10-14 2011-04-21 Mount Sinai School Of Medicine Method of treating memory disorders and enhancing memory using igf-ii compounds
US20150119394A1 (en) * 2012-03-28 2015-04-30 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor Inhibitors
KR101711584B1 (ko) * 2012-12-18 2017-03-02 재단법인 의약바이오컨버젼스연구단 변형된 eprs 단백질의 결정 구조 및 이의 결정화 방법
US10279013B2 (en) 2013-12-19 2019-05-07 Puretein Bioscience Llc Methods for treating an animal
CA3153776A1 (en) 2019-09-09 2021-03-18 The University Of Chicago Combination therapy for the treatment of migraines
US20240050455A1 (en) * 2020-06-01 2024-02-15 Loma Linda University Health Methods of treatment of a cytokine storm

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589867A (en) * 1897-09-14 Clothes-line hanger
US577276A (en) * 1897-02-16 Quarter-saver iv
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5164370A (en) * 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
EP0327503B1 (en) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5028224A (en) * 1990-01-09 1991-07-02 Kimberly-Clark Corporation Apparatus for intermittently depositing particulate material in a substrate
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DE69218948T2 (de) * 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US5126314A (en) * 1991-09-06 1992-06-30 Eastman Kodak Company Mixture of dyes for black dye donor for thermal color proofing
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
JPH08507916A (ja) 1992-06-09 1996-08-27 カイロン コーポレイション Ｍ−ｃｓｆの結晶化
DE69327402T2 (de) 1992-06-12 2000-05-04 Albert Einstein College Of Medicine Of Yeshiva University, Bronx Vorbeugung und behandlung der peripheren neuropathie
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
JPH08500123A (ja) 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5407810A (en) 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
DK0833847T3 (da) 1995-06-22 2003-12-29 Biogen Inc Krystaller af fregmenter af CD40-ligand og deres anvendelse
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
JP3417230B2 (ja) * 1996-09-25 2003-06-16 信越化学工業株式会社 型取り母型用光硬化性液状シリコーンゴム組成物
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2294833A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design
US5876242A (en) * 1997-07-21 1999-03-02 Williams; Hugh D. Remote battery extension apparatus
NZ506091A (en) 1998-01-21 2003-07-25 Brigham & Womens Hospital Circulating insulin-like growth factor-i and prostate cancer risk
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
EP1383793B1 (en) 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
WO2002098914A2 (en) 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
JP3680801B2 (ja) * 2002-02-27 2005-08-10 株式会社デンソー 回転電機の巻線接合方法

Also Published As

Publication number Publication date
JP4489352B2 (ja) 2010-06-23
US20060287235A1 (en) 2006-12-21
WO2002064627A2 (en) 2002-08-22
US20060276397A1 (en) 2006-12-07
EP1358209B1 (en) 2006-12-27
US20060287510A1 (en) 2006-12-21
DK1772464T3 (da) 2009-12-14
NZ548358A (en) 2008-04-30
DE60217066T4 (de) 2010-07-01
MXPA03007042A (es) 2004-05-24
US20050215477A1 (en) 2005-09-29
US7238658B2 (en) 2007-07-03
US7084240B2 (en) 2006-08-01
US7297763B2 (en) 2007-11-20
WO2002064627A3 (en) 2003-07-31
AU2002255508B2 (en) 2008-04-03
NZ548359A (en) 2007-11-30
NZ526672A (en) 2006-10-27
IL156435A0 (en) 2004-01-04
US20060281905A1 (en) 2006-12-14
EP1801120A1 (en) 2007-06-27
DE60217066D1 (de) 2007-02-08
US20060270839A1 (en) 2006-11-30
DE60233359D1 (de) 2009-09-24
JP2009215299A (ja) 2009-09-24
ES2278020T3 (es) 2007-08-01
DK1358209T3 (da) 2007-05-07
CN1703425A (zh) 2005-11-30
EP1772464B1 (en) 2009-08-12
DE60217066T2 (de) 2007-07-12
ZA200304900B (en) 2005-07-27
CN100439397C (zh) 2008-12-03
ATE349469T1 (de) 2007-01-15
ATE439378T1 (de) 2009-08-15
US20060293507A1 (en) 2006-12-28
EP1772464A3 (en) 2007-10-03
IL156435A (en) 2009-09-22
JP2005503329A (ja) 2005-02-03
EP1358209A2 (en) 2003-11-05
ES2331150T3 (es) 2009-12-22
HK1060138A1 (en) 2004-07-30
US7433788B2 (en) 2008-10-07
US7596455B2 (en) 2009-09-29
PL374181A1 (en) 2005-10-03
CA2431033A1 (en) 2002-08-22
KR20040064610A (ko) 2004-07-19
HUP0500733A2 (hu) 2005-10-28
US7354769B2 (en) 2008-04-08
US20020165155A1 (en) 2002-11-07
KR100872613B1 (ko) 2008-12-09
HUP0500733A3 (en) 2010-01-28
EP1772464A2 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
BR0207422A (pt) Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição
Nemeth et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone
BR9912672A (pt) Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r
Matsumoto et al. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid
Defreyn et al. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits
Gomes et al. A mutation in the N-terminus of troponin I that is associated with hypertrophic cardiomyopathy affects the Ca2+-sensitivity, phosphorylation kinetics and proteolytic susceptibility of troponin
Arnett et al. Denervation-induced changes in alpha and beta adrenergic receptors of the rat submandibular gland.
Browning et al. Modulation of Na+× H+ exchange by hydrostatic pressure in isolated bovine articular chondrocytes
US9476889B2 (en) Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
Wang et al. Lanthanum enhances in vitro osteoblast differentiation via pertussis toxin‐sensitive gi protein and ERK signaling pathway
Conway et al. Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2
US10724072B2 (en) Use of phospho-Akt as a biomarker of drug response
Rembold et al. Selected contribution: HSP20 phosphorylation in nitroglycerin-and forskolin-induced sustained reductions in swine carotid media tone
DeSantiago et al. Phospholamban is required for CaMKII-dependent recovery of Ca transients and SR Ca reuptake during acidosis in cardiac myocytes
US20180364254A1 (en) Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
Hall et al. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand
Pellegrin et al. Rho GTPase activation assays
CA2822540A1 (en) Stathmin as a biomarker for furazanobenzimidazoles
Lynch et al. Evidence for high and low affinity a2-receptors
Zoccoli et al. Identification of a rat liver microsomal polypeptide involved in the transport of glucose 6-phosphate. Labeling with 4, 4'-diisothiocyano-1, 2-diphenyl [3H] ethane-2, 2'-disulfonic acid.
Yard et al. Effect of cyclopiazonic acid, an inhibitor of sarcoplasmic reticulum Ca2+‐ATPase, on the frequency‐dependence of the contraction‐relaxation cycle of the guinea‐pig isolated atrium
WO2005012482A3 (en) Assay for identification of bioactive compounds that interact with heat shock protein 90
Amitai et al. The relationship between alpha 1-adrenergic receptor occupation and the mobilization of intracellular calcium.
Chen et al. Effects of extracellular calcium and magnesium on cytosolic calcium concentration in fura‐2‐loaded bovine parathyroid cells
Mehta et al. Relationship between paxillin and myosin phosphorylation during muscarinic stimulation of smooth muscle

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]